Unknown

Dataset Information

0

Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?

ABSTRACT: OBJECTIVE:Determine whether gestational age of 17-hydroxyprogesterone caproate (17-OHPC) initiation is associated with preterm birth (PTB) risk. STUDY DESIGN:We performed a retrospective cohort study using MarketScan® data. The primary outcome was PTB?85% of recommended doses (aRR 1.5; 95%CI 1.2-1.7; p?

SUBMITTER: Carter EB 

PROVIDER: S-EPMC6890226 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Practical considerations with 17-Hydroxyprogesterone caproate for preterm birth prevention: does timing of initiation and compliance matter?

Carter Ebony B EB   Cahill Alison G AG   Olsen Margaret A MA   Macones George A GA   Tuuli Methodius G MG   Stout Molly J MJ  

Journal of perinatology : official journal of the California Perinatal Association 20190619 9

<h4>Objective</h4>Determine whether gestational age of 17-hydroxyprogesterone caproate (17-OHPC) initiation is associated with preterm birth (PTB) risk.<h4>Study design</h4>We performed a retrospective cohort study using MarketScan® data. The primary outcome was PTB < 37 weeks. Rates of PTB were compared between medication initiation at 16-21 weeks versus 21-29 weeks. The association between compliance with weekly 17-OHPC injections and preterm birth rate was tested after adjusting for potential  ...[more]

Similar Datasets

Unknown Pharmacogenomics of 17-alpha hydroxyprogesterone caproate for recurrent preterm birth prevention.
| S-EPMC4266558 | biostudies-literature
Unknown Prevention of preterm birth in triplets using 17 alpha-hydroxyprogesterone caproate: a randomized controlled trial.
| S-EPMC2790283 | biostudies-literature
Unknown Cerclage for the prevention of preterm birth in high risk women receiving intramuscular 17-?-hydroxyprogesterone caproate.
| S-EPMC3991237 | biostudies-literature
Unknown Patient and Provider Perspectives on Acceptability, Access, and Adherence to 17-Alpha-Hydroxyprogesterone Caproate for Preterm Birth Prevention.
| S-EPMC8317597 | biostudies-literature
Unknown 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
| S-EPMC5449222 | biostudies-literature
Unknown Safety review of hydroxyprogesterone caproate in women with a history of spontaneous preterm birth.
| S-EPMC8049867 | biostudies-literature
Unknown Intramuscular 17-hydroxyprogesterone caproate to prevent preterm birth among HIV-infected women in Zambia: study protocol of the IPOP randomized trial.
| S-EPMC6391830 | biostudies-literature
Unknown Weekly 17 alpha-hydroxyprogesterone caproate to prevent preterm birth among women living with HIV: a randomised, double-blind, placebo-controlled trial.
| S-EPMC8476342 | biostudies-literature
Unknown Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation.
| S-EPMC3165062 | biostudies-literature
Unknown Population pharmacokinetics of 17?-hydroxyprogesterone caproate in singleton gestation.
| S-EPMC5137834 | biostudies-literature